Last updated: March 2026
Cerebrolysin (FPF 1070) is a porcine brain-derived peptide mixture containing fragments of CNTF, GDNF, and NGF. With 200+ published clinical studies, it is approved for stroke, TBI, and dementia treatment in 40+ countries — including Russia, China, and much of Europe — though not in the United States. It has been used clinically since the 1950s.
Cerebrolysin (FPF 1070) is a porcine brain-derived peptide mixture from EVER Neuro Pharma (Austria). Used clinically since the 1950s with extensive research across stroke, TBI, and dementia.
Contains peptides including CNTF, GDNF, and NGF fragments. Derived from porcine brain tissue through enzymatic breakdown (1-10 kDa peptides).
Reduces excitotoxic damage, decreases amyloid-beta toxicity, promotes neuronal survival under hypoxia, modulates neuroinflammation.
Promotes hippocampal neurogenesis, enhances synaptic plasticity, improves cholinergic neurotransmission.
MUST be IV or IM injection. Oral is ineffective — peptides would be digested. Significant barrier vs oral nootropics.
Meta-analyses of Cerebrolysin clinical trials.
Context: Most trials from Eastern Europe/Russia where approved for decades. Volume is impressive but many studies older. FDA has not approved despite decades of use elsewhere.
Clinical protocols from published studies. Requires prescription and medical supervision.
Support supplements if pursuing Cerebrolysin therapy (must be prescribed).
Dosing schedules, interaction warnings, and cycle protocols for 50+ compounds — all in one place.
Cerebrolysin is NOT FDA approved and not available in US pharmacies. It requires prescription and must be administered by medical professionals via IV/IM injection. This page is for educational purposes only. Always consult a qualified healthcare provider. Not Available in US Approved 40+ Countries